Sildenafil in the treatment of pulmonary hypertension

Christopher F. Barnett, Roberto Machado

Research output: Contribution to journalReview article

74 Citations (Scopus)

Abstract

The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-selective vasodilators to drugs that specifically target pulmonary vasodilation, endothelial function, and vascular remodeling. Sildenafil is a phosphodiesterase type 5 inhibitor that has an expanding role in the treatment of pulmonary hypertension. Case series and small studies, as well as the first large randomized controlled trial, have demonstrated the safety and efficacy of sildenafil in improving mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index, and exercise tolerance in pulmonary arterial hypertension. It may be useful in adults, children, and neonates after cardiac surgery, with left heart failure, in fibrotic pulmonary disease, high altitude exposure, and thromboembolic disease, and in combination with other therapies for pulmonary hypertension, such as inhaled iloprost. The oral formulation and favorable adverse effect profile make sildenafil an attractive alternative in the treatment of selected patients with pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)411-422
Number of pages12
JournalVascular Health and Risk Management
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Iloprost
Therapeutics
Phosphodiesterase 5 Inhibitors
Exercise Tolerance
Vasodilator Agents
Vasodilation
Vascular Resistance
Pulmonary Artery
Lung Diseases
Thoracic Surgery
Randomized Controlled Trials
Heart Failure
Sildenafil Citrate
Newborn Infant
Safety
Pressure
Lung

Keywords

  • Phosphodiesterase inhibitor
  • Pulmonary hypertension
  • Right heart failure
  • Sildenafil

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Sildenafil in the treatment of pulmonary hypertension. / Barnett, Christopher F.; Machado, Roberto.

In: Vascular Health and Risk Management, Vol. 2, No. 4, 01.12.2006, p. 411-422.

Research output: Contribution to journalReview article

@article{034d61612edc4989b7dc93d0083bfad3,
title = "Sildenafil in the treatment of pulmonary hypertension",
abstract = "The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-selective vasodilators to drugs that specifically target pulmonary vasodilation, endothelial function, and vascular remodeling. Sildenafil is a phosphodiesterase type 5 inhibitor that has an expanding role in the treatment of pulmonary hypertension. Case series and small studies, as well as the first large randomized controlled trial, have demonstrated the safety and efficacy of sildenafil in improving mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index, and exercise tolerance in pulmonary arterial hypertension. It may be useful in adults, children, and neonates after cardiac surgery, with left heart failure, in fibrotic pulmonary disease, high altitude exposure, and thromboembolic disease, and in combination with other therapies for pulmonary hypertension, such as inhaled iloprost. The oral formulation and favorable adverse effect profile make sildenafil an attractive alternative in the treatment of selected patients with pulmonary hypertension.",
keywords = "Phosphodiesterase inhibitor, Pulmonary hypertension, Right heart failure, Sildenafil",
author = "Barnett, {Christopher F.} and Roberto Machado",
year = "2006",
month = "12",
day = "1",
doi = "10.2147/vhrm.2006.2.4.411",
language = "English (US)",
volume = "2",
pages = "411--422",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Sildenafil in the treatment of pulmonary hypertension

AU - Barnett, Christopher F.

AU - Machado, Roberto

PY - 2006/12/1

Y1 - 2006/12/1

N2 - The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-selective vasodilators to drugs that specifically target pulmonary vasodilation, endothelial function, and vascular remodeling. Sildenafil is a phosphodiesterase type 5 inhibitor that has an expanding role in the treatment of pulmonary hypertension. Case series and small studies, as well as the first large randomized controlled trial, have demonstrated the safety and efficacy of sildenafil in improving mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index, and exercise tolerance in pulmonary arterial hypertension. It may be useful in adults, children, and neonates after cardiac surgery, with left heart failure, in fibrotic pulmonary disease, high altitude exposure, and thromboembolic disease, and in combination with other therapies for pulmonary hypertension, such as inhaled iloprost. The oral formulation and favorable adverse effect profile make sildenafil an attractive alternative in the treatment of selected patients with pulmonary hypertension.

AB - The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-selective vasodilators to drugs that specifically target pulmonary vasodilation, endothelial function, and vascular remodeling. Sildenafil is a phosphodiesterase type 5 inhibitor that has an expanding role in the treatment of pulmonary hypertension. Case series and small studies, as well as the first large randomized controlled trial, have demonstrated the safety and efficacy of sildenafil in improving mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index, and exercise tolerance in pulmonary arterial hypertension. It may be useful in adults, children, and neonates after cardiac surgery, with left heart failure, in fibrotic pulmonary disease, high altitude exposure, and thromboembolic disease, and in combination with other therapies for pulmonary hypertension, such as inhaled iloprost. The oral formulation and favorable adverse effect profile make sildenafil an attractive alternative in the treatment of selected patients with pulmonary hypertension.

KW - Phosphodiesterase inhibitor

KW - Pulmonary hypertension

KW - Right heart failure

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=33846911349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846911349&partnerID=8YFLogxK

U2 - 10.2147/vhrm.2006.2.4.411

DO - 10.2147/vhrm.2006.2.4.411

M3 - Review article

VL - 2

SP - 411

EP - 422

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 4

ER -